ArticleFrontiers in immunology2026
Nocardia rubra cell wall skeleton-induced MARCO expression: implications for improved phagocytosis and cytokine secretion in tumor-associated macrophages.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nocardia rubra cell wall skeleton (Nr-CWS) demonstrates a significant therapeutic effect against human papillomavirus (HPV) infection, but its precise immunomodulatory mechanisms warrant further investigation. This study investigates how Nr-CWS influences tumor-associated macrophages (TAMs) immune functions through macrophage receptor with collagenous structure (MARCO)-mediated mechanisms. Methods: Cervical tissues of three cervical intraepithelial neoplasia (CIN) patients receiving Nr-CWS monotherapy and HPV infection turning negative were collected before and after treatment, and gene microarray analysis was performed. MARCO expression and immune cell infiltration were further analyzed using transcriptomic data from 33 tumor types in The Cancer Genome Atlas (TCGA). In vitro, TAMs derived from Human Monocytic Leukemia Cell Line 1 (THP-1) cells were treated with Nr-CWS, and changes in MARCO expression, cytoskeletal rearrangement, pseudopod length, lysosome count, and cytokine secretion were assessed. MARCO inhibition experiments were also performed. Results: Gene microarray revealed significant upregulation of MARCO, a key phagosome pathway gene, post-treatment. TCGA analysis indicated that MARCO expression is significantly altered in most tumor tissues compared to normal tissues and is associated with the infiltration of multiple immune cell types, with a particularly strong correlation to macrophage abundance. Histologically, Nr-CWS increased MARCO⁺ macrophages in cervical tissues. Discussion: The study demonstrates that Nr-CWS enhances TAM anti-tumor immune function via MARCO upregulation, leading to improved phagocytic activity and proinflammatory response. These findings align with genomic and cellular evidence, suggesting MARCO as a key mediator in Nr-CWS-induced macrophage reprogramming, with implications for HPV-related neoplasia immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.